Abstract:Abstract BACKGROUND: Leuprorelin (Enantone®) is a gonadotropin-releasing hormone (GnRH) analogue used worldwide to treat central precocious puberty (CPP). This clinical trial aimed to evaluate the long-term safety and efficacy of leuprorelin in treating Chinese CPP children. Methods: This is the first, prospective, open-label, and multicenter study conducted from 2015 to 2018, in China. As a large interventional study, it included a four-week screening period, a 96-week treatment period, and a four-week safety follow-up period. Eligible subjects were treated with leuprorelin subcutaneously once every four weeks for 96 weeks. At the beginning of the study, subjects whose body weight ≥20 kg received a dose of 3.75 mg and those <20 kg received a dose of 1.88 mg and then the dose was allowed to be adjusted during the study based on subject’s condition and investigator’s judgment. The primary endpoint was the incidence of adverse events during treatment, and the secondary endpoint was the percentage of subjects who had regression or no progression in Tanner stage at Week 96 compared with baseline. Results: A total of 307 CPP patients from 11 Chinese medical centers received leuprorelin, of which 305 (99.3%) were girls and 2 were boys (0.7%), with a mean (±SD) age of 7.95±0.982 years and a mean height of 133.68±7.108 cm. Two hundred eighty-three (92.2%) patients completed the 96-week treatment period. Two hundred fifty-two patients (82.1%) reported treatment-emergent adverse events (TEAEs)—most of which (79.5%) were mild to moderate. Only 33 (10.7%) patients experienced TEAEs that were considered related to leuprorelin. The most frequent (>2%) drug-related TEAEs were injection site induration (4.6%, 14/307) and vaginal bleeding (2.3%, 7/305). After the 96-week treatment period, 83.5% female subjects had regression or no progression in Tanner stage compared with baseline (95% CI: 78.68%, 87.62%) and the 2 male subjects had progression of 1 point in Tanner stage genital score occurred at Week 12 and then remained stable throughout the study. By the end of the treatment period, the majority of subjects had decreased GnRH stimulated peak LH and FSH, as well as reduced sex hormone levels and bone age/chronological age ratio compared with baseline. The subjects also had increased predicted adult height and BMI after treatment. Conclusions: This Chinese study demonstrated that CPP was effectively treated in most patients who received leuprorelin (Enantone®) for nearly two years. Any drug-related adverse events were reported with low incidence (<5%) and were consistent with the known safety profile of leuprorelin. Leuprorelin was shown to be well tolerated and effective in the management of CPP in Chinese patients.

EFFECT OF CYPROTERONE ACETATE (CA) ON GROWTH AND ENDOCRINE FUNCTION IN PRECOCIOUS PUBERTY

[Long-Acting Gonadotropin-Releasing Hormone Analogue in Treatment of Idiopathic Central Precocious Puberty in Girls].

Effect of cyproterone acetate on adrenocortical function in children with precocious puberty.

ADRENOCORTICAL FUNCTION IN CHILDREN WITH PRECOCIOUS SEXUAL DEVELOPMENT DURING TREATMENT WITH CYPROTERONE ACETATE

Effects of gonadotropin releasing hormone analog and growth hormone on height in girls with idiopathic central precocious puberty]

SUN-094 Long-Term Safety and Efficacy of Leuprorelin in Treating Central Precocious Puberty: A Large, Open-Label, Multicenter, Phase IV Study in China

Relationship of Plasma Ghrelin and Adenohypophyseal Hormone Levels in Female Precocious Puberty

The Clinical Effects of Gonadotropin-Releasing Hormone Agonists for the Treatment of Children Patients with Central Precocious Puberty.

Abstract 29: Effect of gonadotropin releasing hormone analog treatment on final adult height in children with congenital adrenal hyperplasia complicated by central precocious puberty

Long-Term Outcomes of Treatments for Central Precocious Puberty or Early and Fast Puberty in Chinese Girls

Growth, Growth Hormone and Sex Steroid Secretion in Girls with Central Precocious Puberty Treated with a Gonadotrophin Releasing Hormone (GnRH) Analogue

Effects of Treatment on Female Idiopathic Central Precious Puberty with Gonodotrophine-Releasing Hormone Analogue and Growth Hormone.

177 DECREASE IN GROWTH HORMONE (GH) AND SOMATOMEDIN C (SOMC) DURING LHRH AGONIST (LHRHa) TREATMENT OF CENTRAL PRECOCIOUS PUBERTY (CPP)

489 DECREASE IN GROWTH HORMONE (GH) AND SOMATOMEDIN (SOMC) DURING LHRH AGONIST (LHRHa) TREATMENT OF CENTRAL PRECOCIOUS PUBERTY (CPP)

Clinical Study on Treatment of Female Idiopathic Precocious Puberty with Combined Therapy of Chinese Medicine and Megestrol Acetate

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment

Metabolic Outcomes, Bone Health, and Risk of Polycystic Ovary Syndrome in Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogues

SUN-042 Low Dose Cyproterone Acetate for the Treatment of Transgender Women - a Retrospective Study

Effect of Triptorelin 3.75 Mg Subcutaneously Injection Every 6 Weeks on Adult Height in Girls with Idiopathic Central Precocious Puberty

The effect of gonadoliberin analog treatment in precocious puberty on polycystic ovarian syndrome prevalence in adulthood